Literature DB >> 289408

Membrane receptors of human leukaemic myeloid cells: sequential expression of the gamma Fc receptor.

G F Burns, J C Cawley.   

Abstract

An immunological surface marker study was performed on 13 patients with a variety of myeloid leukaemias. It was shown that expression of the receptor for the Fc of IgG (gamma FcR) starts to take place at the promyelocyte stage, and that the receptor is present on more mature granulocytic cells, but is absent from myeloblasts. Myeloblasts and promyelocytes are negative for the complement receptor CR2. Monoblasts, unlike myelobasts, were shown to express a gamma FcR and, to a lesser extent, CR2. Receptor expression therefore appears to be an earlier event in monocytic development. The possible diagnostic value of immunological marker studies in myeloid disorders is considered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 289408     DOI: 10.1111/j.1365-2141.1979.tb01162.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Maturation-linked expression of C3b and C3b' receptors on developing human bone marrow and peripheral blood granulocytes.

Authors:  C S Scott
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

2.  Immune complexes and circulating antibodies against autologous leukaemic cells in patients with acute leukaemias.

Authors:  M Bertini; G Galetto; P M Comoglio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

3.  Ontogeny of Fc receptors and complement receptor (CR3) during human myeloid differentiation.

Authors:  H B Fleit; S D Wright; C J Durie; J E Valinsky; J C Unkeless
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

4.  Membrane Fc-IgG and C3b receptors on myeloid leukaemia cells: a comparison with cytoplasmic acid naphthyl acetate esterase cytochemistry.

Authors:  C S Scott; A G Bynoe; D C Linch; C Allen; D Hough; B E Roberts
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.